The most-cited Articles on
Glioblastoma

Akmal M, et al., Glioblastome Multiforme: A Bibliometric Analysis. World Neurosurg 2020


Home > Publications > The most-cited articles > Diffuse astrocytic and oligodendroglial tumors > Akmal M, 2020


Contents

Akmal M, Hasnain N, Rehan A, Iqbal U, Hashmi S, Fatima K, Farooq MZ, Khosa F, Siddiqi J, Khan MK.
Glioblastome Multiforme: A Bibliometric Analysis.
World Neurosurg. 2020 Apr;136:270-282. doi: 10.1016/j.wneu.2020.01.027. Epub 2020 Jan 14.PMID: 31953095. Bibliometric analysis.




Classification


Epidemiology, Risk factors


Etiology, Pathogenesis, Pathology


Overall management


Treatment



Classification


Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P.
Grading of astrocytomas. A simple and reproducible method.
Cancer. 1988 Nov 15;62(10):2152-65. doi: 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t. PMID: 3179928. Tool development.



Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK.
The WHO classification of tumors of the nervous system.
J Neuropathol Exp Neurol. 2002 Mar 1;61(3):215-25. doi: 10.1093/jnen/61.3.215. PMID: 11895036. Review.



Kleihues P, Burger PC, Scheithauer BW.
The new WHO classification of brain tumours.
Brain Pathol. 1993 Jul;3(3):255-68. doi: 10.1111/j.1750-3639.1993.tb00752.x. PMID: 8293185. Review.



Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
Acta Neuropathol. 2016 May 9. 2016;131(6):803-20. doi: 10.1007/s00401-016-1545-1. PMID: 27157931. Review.



Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P.
The 2007 WHO classification of tumours of the central nervous system.
Acta Neuropathol. 2007 Jul 6. 2007;114(2):97-109. doi: 10.1007/s00401-007-0243-4. PMID: 17618441. Review.
Erratum in: Acta Neuropathol. 2007 Sep 28. 2007;114(5):547. doi: 10.1007/s00401-007-0278-6. Correction.



Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K.
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
Cancer Cell. 2006 Mar 1;9(3):157-73. doi: 10.1016/j.ccr.2006.02.019. PMID: 16530701. Laboratory investigation.



Epidemiology, Risk factors

Dolecek TA, Propp JM, Stroup NE, Kruchko C.
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.
Neuro Oncol. 2012 Nov 1;14 Suppl 5(Suppl 5):v1-49. doi: 10.1093/neuonc/nos218. PMID: 23095881. Review.
Erratum in: Neuro Oncol. 2013 May 1;15(5):646-7. doi: 10.1093/neuonc/nos389. Correction.



Ohgaki H, Kleihues P.
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
J Neuropathol Exp Neurol. 2005 Jun 1;64(6):479-89. doi: 10.1093/jnen/64.6.479. PMID: 15977639. Retrospective analysis & Review.



Ohgaki H, Kleihues P.
Epidemiology and etiology of gliomas.
Acta Neuropathol. 2005 Feb 1;109(1):93-108. doi: 10.1007/s00401-005-0991-y. PMID: 15685439. Review.



Etiology, Pathogenesis, Pathology

Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY.
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas.
Proc Natl Acad Sci USA. 2000 Nov 7;97(23):12846-51. doi: 10.1073/pnas.97.23.12846. PMID: 11070094. Laboratory investigation.
Erratum in: Proc Natl Acad Sci USA. 2001 Jan 16;98(2):777. doi: 10.1073/pnas.98.2.777-d. Correction.



Abbott NJ, Rönnbäck L, Hansson E.
Astrocyte-endothelial interactions at the blood-brain barrier.
Nat Rev Neurosci. 2006 Jan 1;7(1):41-53. doi: 10.1038/nrn1824. PMID: 16371949. Review.



Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A.
Analysis of the IDH1 codon 132 mutation in brain tumors.
Acta Neuropathol. 2008 Nov 5;116(6):597-602. doi: 10.1007/s00401-008-0455-2. PMID: 18985363. Laboratory investigation.



Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN.
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
Nature. 2006 Oct 18. 2006;444(7120):756-60. doi: 10.1038/nature05236. PMID: 17051156. Laboratory investigation.



Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN.
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
Cancer Res. 2006 Aug 15;66(16):7843-8. doi: 10.1158/0008-5472.CAN-06-1010. PMID: 16912155. Laboratory investigation.



Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP.
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Cancer Res. 2007 May 1;67(9):4010-5. doi: 10.1158/0008-5472.CAN-06-4180. PMID: 17483311. Laboratory investigation.



Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR.
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.
Proc Natl Acad Sci USA. 2007 Dec 6;104(50):20007-12. doi: 10.1073/pnas.0710052104. PMID: 18077431. Tool development.



Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network.
The somatic genomic landscape of glioblastoma.
Cell. 2013 Oct 10;155(2):462-77. doi: 10.1016/j.cell.2013.09.034. PMID: 24120142. Laboratory investigation.
Erratum in: Cell. 2014 Apr 24;157(3):753. doi: 10.1016/j.cell.2014.04.004. Correction.



Chan JA, Krichevsky AM, Kosik KS.
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 2005 Jul 15;65(14):6029-33. doi: 10.1158/0008-5472.CAN-05-0137. PMID: 16024602. Laboratory investigation.



Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF.
A restricted cell population propagates glioblastoma growth after chemotherapy.
Nature. 2012 Aug 1;488(7412):522-6. doi: 10.1038/nature11287. PMID: 22854781. Laboratory investigation.



Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG.
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 2005 Jul 18;334(4):1351-8. doi: 10.1016/j.bbrc.2005.07.030. PMID: 16039986. Laboratory investigation.



Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A.
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity.
Curr Biol. 2006 Dec 28. 2007;17(2):165-72. doi: 10.1016/j.cub.2006.11.033. PMID: 17196391. Laboratory investigation.
Erratum in: Curr Biol. 2007 Jan 22;17(2):192. doi: 10.1016/j.cub.2007.01.024. Correction.



Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM.
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 2009 Nov 22;462(7274):739-44. doi: 10.1038/nature08617. PMID: 19935646. Laboratory investigation.
Addendum in: Nature. 2010 Jun 17;465(7300):966. doi: 10.1038/nature09132. PMID: 20559394. Addendum.



Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G.
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.
Cancer Cell. 2008 Mar 11;13(3):206-20. doi: 10.1016/j.ccr.2008.01.034. PMID: 18328425. Laboratory investigation.



Fulda S, Wick W, Weller M, Debatin KM.
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Nat Med. 2002 Jul 15;8(8):808-15. doi: 10.1038/nm735. PMID: 12118245. Laboratory investigation.



Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK.
Malignant astrocytic glioma: genetics, biology, and paths to treatment.
Genes Dev. 2007 Nov 1;21(21):2683-710. doi: 10.1101/gad.1596707. PMID: 17974913. Review.



Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM.
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators.
Mol Cell Biol. 2008 Jun 30;28(17):5369-80. doi: 10.1128/MCB.00479-08. PMID: 18591254. Laboratory investigation.



Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A.
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma.
Cancer Res. 2004 Oct 1;64(19):7011-21. doi: 10.1158/0008-5472.CAN-04-1364. PMID: 15466194. Laboratory investigation.



Giese A, Bjerkvig R, Berens ME, Westphal M.
Cost of migration: invasion of malignant gliomas and implications for treatment.
J Clin Oncol. 2003 Apr 15;21(8):1624-36. doi: 10.1200/JCO.2003.05.063. PMID: 12697889. Review.



Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN.
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.
Nat Genet. 2000 May;25(1):55-7. doi: 10.1038/75596. PMID: 10802656. Laboratory investigation.



Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT.
Angiogenesis in brain tumours.
Nat Rev Neurosci. 2007 Aug;8(8):610-22. doi: 10.1038/nrn2175. PMID: 17643088. Review.



Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S.
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Cell Death Differ. 2004 Jan 9;11(4):448-57. doi: 10.1038/sj.cdd.4401359. PMID: 14713959. Laboratory investigation.



Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA.
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
Cancer Cell. 2006 May 1;9(5):391-403. doi: 10.1016/j.ccr.2006.03.030. PMID: 16697959. Laboratory investigation.



Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R.
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
Science. 1997 Mar 28;275(5308):1943-7. doi: 10.1126/science.275.5308.1943. PMID: 9072974. Laboratory investigation.



Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN.
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.
Cancer Cell. 2009 Jun 2;15(6):501-13. doi: 10.1016/j.ccr.2009.03.018. PMID: 19477429. Laboratory investigation.



Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J.
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.
Nature. 1985 Jan 10;313(5998):144-7. doi: 10.1038/313144a0. PMID: 2981413. Laboratory investigation.



Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS.
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Mol Cancer. 2006 Dec 2;5:67. doi: 10.1186/1476-4598-5-67. PMID: 17140455. Laboratory investigation.



Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA.
Malignant glioma: genetics and biology of a grave matter.
Genes Dev. 2001 Jun 1;15(11):1311-33. doi: 10.1101/gad.891601. PMID: 11390353. Review.



McLendon R, et al., Cancer Genome Atlas Research Network.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature. 2008 Sep 4. 2008;455(7216):1061-8. doi: 10.1038/nature07385. PMID: 18772890. Laboratory investigation.
Erratum in: Nature. 2013 Feb 6. 2013;494(7438):506. doi. 10.1038/nature11903. Correction.



Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ.
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Proc Natl Acad Sci USA. 1994 Aug 2;91(16):7727-31. doi: 10.1073/pnas.91.16.7727. PMID: 8052651. Laboratory investigation.



Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K; Cancer Genome Atlas Research Network.
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Cancer Cell. 2010 Apr 15;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. PMID: 20399149. Laboratory investigation.



Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN.
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
Cancer Res. 2003 Apr 1;63(7):1602-7. PMID: 12670911. Laboratory investigation.



Ohgaki H, Kleihues P.
Genetic pathways to primary and secondary glioblastoma.
Am J Pathol. 2007 May 1;170(5):1445-53. doi: 10.2353/ajpath.2007.070011. PMID: 17456751. Review.



Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO.
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.
Nat Med. 2006 Dec 10. 2007;13(1):84-8. doi: 10.1038/nm1517. PMID: 17159987. Laboratory investigation.



Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.
An integrated genomic analysis of human glioblastoma multiforme.
Science. 2008 Sep 4;321(5897):1807-12. doi: 10.1126/science.1164382. PMID: 18772396. Laboratory investigation.



Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE.
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.
Science. 2014 Jun 20;344(6190):1396-401. doi: 10.1126/science.1254257. PMID: 24925914. Laboratory investigation.



Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL.
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.
Nature. 2006 Dec 7;444(7120):761-5. doi: 10.1038/nature05349. PMID: 17151667. Laboratory investigation.



Plate KH, Breier G, Weich HA, Risau W.
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
Nature. 1992 Oct 29;359(6398):845-8. doi: 10.1038/359845a0. PMID: 1279432. Laboratory investigation.



Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R.
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.
Nature. 2010 Nov 21;468(7325):824-8. doi: 10.1038/nature09557. PMID: 21102434. Laboratory investigation.
Erratum in: Nature. 2011 Jan 19;469(7330):432. doi: 10.1038/nature09734. Correction.
Erratum in: Nature. 2011 Sep 7;477(7363):238
. doi: 10.1038/nature10410. Correction.



Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Frühwald MC, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N.
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Nature. 2012 Jan 29;482(7384):226-31. doi: 10.1038/nature10833. PMID: 22286061. Laboratory investigation.
Erratum in: Nature. 2012 Mar 28;484(7392):130. doi: 10.1038/nature11026. Correction.



Shweiki D, Itin A, Soffer D, Keshet E.
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
Nature. 1992 Oct 29;359(6398):843-5. doi: 10.1038/359843a0. PMID: 1279431. Laboratory investigation.



Seoane J, Le HV, Shen L, Anderson SA, Massagué J.
Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation.
Cell. 2004 Apr 16;117(2):211-23. doi: 10.1016/s0092-8674(04)00298-3. PMID: 15084259. Laboratory investigation.



Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG.
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
BMC Med. 2008 Jun 24;6:14. doi: 10.1186/1741-7015-6-14. PMID: 18577219. Laboratory investigation.



Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB.
Identification of human brain tumour initiating cells.
Nature. 2004 Nov 18;432(7015):396-401. doi: 10.1038/nature03128. PMID: 15549107. Laboratory investigation.



Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB.
Identification of a cancer stem cell in human brain tumors.
Cancer Res. 2003 Sep 15;63(18):5821-8. PMID: 14522905. Laboratory investigation.



Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO.
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.
Nat Cell Biol. 2008 Nov 16. 2008;10(12):1470-6. doi: 10.1038/ncb1800. PMID: 19011622. Laboratory investigation.



Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV.
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat Genet. 1997 Apr 1;15(4):356-62. doi: 10.1038/ng0497-356. PMID: 9090379. Laboratory investigation.



Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA.
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Science. 2007 Sep 13;318(5848):287-90. doi: 10.1126/science.1142946. PMID: 17872411. Laboratory investigation.



Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM.
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Cancer Cell. 2012 Oct 16;22(4):425-37. doi: 10.1016/j.ccr.2012.08.024. PMID: 23079654. Laboratory investigation.



Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866. PMID: 22343889. Laboratory investigation.



Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network.
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020. PMID: 20129251. Laboratory investigation.



Visvader JE, Lindeman GJ.
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.
Nat Rev Cancer. 2008 Sep 11;8(10):755-68. doi: 10.1038/nrc2499. PMID: 18784658. Review.



Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V.
Glioblastoma stem-like cells give rise to tumour endothelium.
Nature. 2010 Nov 21;468(7325):829-33. doi: 10.1038/nature09624. PMID: 21102433. Laboratory investigation.



Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, Zhang J, Gajjar A, Dyer MA, Mullighan CG, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Ellison DW, Zhang J, Baker SJ; St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project.
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
Nat Genet. 2012 Jan 29;44(3):251-3. doi: 10.1038/ng.1102. PMID: 22286216. Laboratory investigation.



Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD.
IDH1 and IDH2 mutations in gliomas.
N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710. PMID: 19228619. Laboratory investigation.



Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y.
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Science. 2009 Apr 10;324(5924):261-5. doi: 10.1126/science.1170944. PMID: 19359588. Laboratory investigation.



Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ.
Loss of PTEN facilitates HIF-1-mediated gene expression.
Genes Dev. 2000 Feb 15;14(4):391-6. doi: 10.1101/gad.14.4.391? PMID: 10691731. Laboratory investigation.



Overall management

Hochberg FH, Pruitt A.
Assumptions in the radiotherapy of glioblastoma.
Neurology. 1980 Sep 1;30(9):907-11. doi: 10.1212/wnl.30.9.907. PMID: 6252514. Retrospective analysis.



Omuro A, DeAngelis LM.
Glioblastoma and other malignant gliomas: a clinical review.
JAMA. 2013 Nov 6;310(17):1842-50. doi: 10.1001/jama.2013.280319. PMID: 24193082. Review



Wen PY, Kesari S.
Malignant gliomas in adults.
N Engl J Med. 2008 Jul 31;359(5):492-507. doi: 10.1056/NEJMra0708126. PMID: 18669428. Review.
Erratum in: N Engl J Med. 2008 Aug 21;359(8):877. doi: 10.1056/NEJMx080027. Correction.



Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
J Clin Oncol. 2010 Mar 15;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. PMID: 20231676. Guidelines.



Treatment

Barth RF, Coderre JA, Vicente MG, Blue TE.
Boron neutron capture therapy of cancer: current status and future prospects.
Clin Cancer Res. 2005 Jun 1;11(11):3987-4002. doi: 10.1158/1078-0432.CCR-05-0035. PMID: 15930333. Review.



Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK.
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007 Jan 15;11(1):83-95. doi: 10.1016/j.ccr.2006.11.021 . PMID: 17222792. Phase 2 trial.



Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ.
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Lancet Oncol. 2008 May 1;9(5):453-61. doi: 10.1016/S1470-2045(08)70125-6. PMID: 18452856. Review.



Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC.
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Lancet. 1995 Apr 22;345(8956):1008-12. doi: 10.1016/s0140-6736(95)90755-6. PMID: 7723496. Randomized trial.



Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T.
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345. PMID: 24552318. Phase 3 trial.



Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al.
Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.
J Natl Cancer Inst. 1993 May 5;85(9):704-10. doi: 10.1093/jnci/85.9.704. PMID: 8478956. Recursive partitioning analysis.



Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP.
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.
Cancer. 1993 Apr 15;71(8):2585-97. doi: 10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s. PMID: 8453582. Meta-analysis.



Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
J Clin Oncol. 2009 Aug 31;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. PMID: 19720927. Phase 2 trial.



Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP.
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573. PMID: 24552317. Randomized trial.



Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 2005 Mar 10;352(10):997-1003. doi: 10.1056/NEJMoa043331. PMID: 15758010. Clinical trial.



Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA.
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
J Clin Oncol. 2008 Dec 29. 2009;27(5):740-5. doi: 10.1200/JCO.2008.16.3055. PMID: 19114704. Phase 2 trial.



Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R.
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.
J Neurosurg. 2001 Aug;95(2):190-8. doi: 10.3171/jns.2001.95.2.0190. PMID: 11780887. Retrospective analysis.



Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL.
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
Gene Ther. 2000 May 25;7(10):867-74. doi: 10.1038/sj.gt.3301205. PMID: 10845725. Phase 1 trial.



Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
N Engl J Med. 2005 Nov 10;353(19):2012-24. doi: 10.1056/NEJMoa051918. PMID: 16282176. Clinical study.
Erratum in: N Engl J Med. 2006 Feb 23;354(8):884. doi: 10.1056/NEJMx060009. Correction.



Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A.
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.
Nature. 1994 Feb 10;367(6463):576-9. doi: 10.1038/367576a0. PMID: 8107827. Laboratory investigation.



Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38. PMID: 18316689. Retrospective analysis.



Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P.
Genetic pathways to glioblastoma: a population-based study.
Cancer Res. 2004 Oct 1;64(19):6892-9. doi: 10.1158/0008-5472.CAN-04-1337. PMID: 15466178. Retrospective analysis.



Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ; ALA-Glioma Study Group.
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.
Lancet Oncol. 2006 Apr 13;7(5):392-401. doi: 10.1016/S1470-2045(06)70665-9. PMID: 16648043. Phase 3 trial.



Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Lancet Oncol. 2009 Mar 9. 2009;10(5):459-66
. doi: 10.1016/S1470-2045(09)70025-7. PMID: 19269895. Phase 3 trial.



Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330. PMID: 15758009. Phase 3 trial.



Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S.
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
J Clin Oncol. 2002 Mar 1;20(5):1375-82. doi: 10.1200/JCO.2002.20.5.1375. PMID: 11870182. Phase 2 trial.



Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M.
Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.
J Magn Reson Imaging. 1999 Jan;9(1):53-60. doi: 10.1002/(sici)1522-2586(199901)9:1<53::aid-jmri7>3.0.co;2-2. PMID: 10030650. Prospective study.



Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ.
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.
CA Cancer J Clin. 2010 May 5;60(3):166-93
. doi: 10.3322/caac.20069. PMID: 20445000. Review.



Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
J Clin Oncol. 2007 Oct 20;25(30):4722-9. doi: 10.1200/JCO.2007.12.2440. PMID: 17947719. Phase 2 trial.



Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS.
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clin Cancer Res. 2007 Feb 15;13(4):1253-9. doi: 10.1158/1078-0432.CCR-06-2309. PMID: 17317837. Phase 2 trial.



Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA.
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
N Engl J Med. 1980 Dec 4;303(23):1323-9. doi: 10.1056/NEJM198012043032303. PMID: 7001230. Prospective study.



Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA.
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
J Neurosurg. 1978 Sep;49(3):333-43. doi: 10.3171/jns.1978.49.3.0333. PMID: 355604. Prospective study.



Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z.
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Neuro Oncol. 2003 Apr 1;5(2):79-88. doi: 10.1093/neuonc/5.2.79. PMID: 12672279. Phase 3 trial.



Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK.
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
J Clin Oncol. 1999 Aug 1;17(8):2572-8. doi: 10.1200/JCO.1999.17.8.2572. PMID: 10561324. Phase 2 trial.



Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA.
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Br J Cancer. 2000 Aug 8;83(5):588-93. doi: 10.1054/bjoc.2000.1316. PMID: 10944597. Phase 2 trial.





Bottom